Europe Genetic Testing Market Size and Forecast

TheEurope genetic testing market is becoming an increasingly important part of modern healthcare as genomic technologies move from specialized applications into routine diagnosis, disease prevention, personalized treatment, and reproductive healthcare. According to Renub Research, the Europe genetic testing market is expected to reach US$14.61 billion by 2034, rising from US$7.25 billion in 2025 and registering a CAGR of 8.1% during 2026–2034. The market is being supported by the expansion of precision medicine, technological innovation, greater awareness of inherited conditions, and broader adoption of genomic healthcare solutions.

Genetic testing is increasingly being used for more than identifying rare inherited disorders. Its applications now include cancer risk assessment, cardiovascular disease, neurological conditions, prenatal screening, pharmacogenomics, and population-level health programs. As healthcare systems across Europe place greater emphasis on early diagnosis and individualized care, genetic testing is becoming a valuable tool for improving clinical decision-making.

The market's development is also being supported by advances in sequencing, laboratory automation, bioinformatics, and data interpretation. Together, these developments are improving testing efficiency and expanding the range of genetic information that healthcare professionals can use.

Why Is Genetic Testing Becoming More Important in Europe?

Genetic testing provides information about variations in an individual's DNA that can help identify inherited conditions, disease risks, or potential responses to particular treatments. Its growing importance in Europe is closely connected to the shift toward preventive and personalized healthcare.

Hospitals, diagnostic laboratories, research institutions, and private healthcare providers are expanding genomic testing capabilities to meet increasing clinical requirements. Genetic information can support earlier diagnosis, help physicians assess hereditary risks, and contribute to treatment selection.

The growing use of genetic testing in oncology is particularly significant. Genetic analysis can help identify inherited cancer susceptibility and molecular characteristics that may influence treatment strategies. Similar applications are developing in cardiovascular medicine, rare diseases, neurological disorders, and reproductive healthcare.

Europe's established healthcare infrastructure and strong biomedical research environment provide a favorable foundation for this expansion. Governments and healthcare systems are also supporting genomic research, rare disease initiatives, and screening programs, helping genetic testing become more integrated into healthcare delivery.

What Are the Major Growth Drivers of the Europe Genetic Testing Market?

Expansion of Population and Newborn Genomic Screening

Newborn and population screening initiatives are creating important opportunities for genetic testing across Europe. Early identification of genetic disorders can allow healthcare professionals to intervene before symptoms become severe, particularly when effective treatment or dietary management is available.

The source highlights Belgium's BabyDetect program, supported by EUR 25 million in government grants, which examines newborns for more than 200 illnesses. The United Kingdom's Newborn Genomes Programme is also sequencing 200,000 infants. Meanwhile, a Horizon Europe initiative is working to harmonize genomic data pipelines across seven member states.

These initiatives demonstrate the growing focus on identifying actionable genetic conditions at an early stage. As screening programs expand, demand can increase for sequencing platforms, laboratory services, genomic databases, and sophisticated variant-interpretation capabilities.

Rising Demand for Hereditary Cancer Testing

The growing emphasis on hereditary cancer detection is another major factor supporting market development. Genetic testing can identify inherited variations associated with elevated risks of certain cancers, allowing healthcare providers and families to make more informed decisions about screening and preventive care.

The source notes that updated European oncology guidelines have expanded eligibility for germline testing among certain cancer patients. Multigene panels are also becoming increasingly relevant because they can examine multiple genes in a single test rather than relying on sequential single-gene testing.

Family cascade testing is another important application. When an actionable inherited variation is identified in one individual, relatives may also undergo testing to determine whether they carry the same variation. This can increase opportunities for early intervention and targeted monitoring.

Growing Adoption of NGS-Based Comprehensive Testing

Next-generation sequencing is transforming genetic testing by allowing laboratories to examine large numbers of genes simultaneously. Comprehensive panels can increase diagnostic efficiency, particularly for diseases with multiple possible genetic causes.

According to the provided source, NGS tumor and rare-disease panels are being reimbursed by national health systems, supporting broader clinical adoption. The source also indicates that comprehensive approaches can produce higher diagnostic yields than sequential single-gene testing.

Greater reimbursement clarity encourages healthcare providers and laboratories to invest in sequencing capacity, reagents, bioinformatics infrastructure, and electronic health record integration. This creates a broader ecosystem around genomic diagnostics rather than limiting testing to individual laboratory procedures.

How Is Technology Reshaping Genetic Testing?

Next-Generation Sequencing and Whole Genome Analysis

Technological development is one of the strongest foundations of the European genetic testing market. Next-generation sequencing, whole genome sequencing, exome sequencing, PCR, chromosomal microarrays, and bioinformatics have improved the ability to identify genetic variations.

These technologies allow laboratories to process increasingly complex genomic information while improving speed, scalability, and analytical capabilities. Whole genome and exome approaches can be particularly useful when a patient's symptoms do not point clearly toward a single genetic condition.

As sequencing costs and turnaround times become more manageable, broader clinical applications become possible.

Artificial Intelligence and Genomic Data Interpretation

Genetic testing produces large and complex datasets that require careful interpretation. Artificial intelligence and advanced analytics can assist healthcare professionals in analyzing genomic information and identifying potentially relevant variations.

Improved computational tools can help laboratories manage large volumes of genetic data and support more efficient interpretation. Integration with clinical records can also make genomic information more accessible during diagnosis and treatment planning.

However, technology does not eliminate the need for qualified professionals. Genetic results often require clinical context, appropriate counseling, and careful communication with patients.

What Challenges Could Restrain Market Growth?

Shortage of Certified Genetic Counselors

One of the most significant challenges is the shortage of trained genetic counselors. As genetic testing becomes more common, patients need appropriate pre-test and post-test counseling to understand what results mean and what actions may follow.

The provided source estimates that Europe needs approximately 4,000 additional trained genetic counselors to address current caseloads, while universities produce around 200 new counselors annually. The United Kingdom is also described as relying increasingly on tele-genetics and group-based approaches because of limited counselor availability.

This shortage can create waiting periods and limit access to testing, especially for complex prenatal, oncology, and inherited-disease cases. Expanding training programs and using appropriate digital counseling models could help address this constraint.

Ethical, Legal, and Privacy Concerns

Genetic information is exceptionally sensitive because it can reveal information not only about an individual but potentially about biological relatives. Consequently, privacy, informed consent, data security, and responsible information sharing are central issues in the development of genomic healthcare.

Patients may have concerns about how their genetic information is stored, analyzed, or shared. Differences in national rules can also create operational complexity for cross-border genomic services.

Maintaining public confidence will therefore depend on transparent consent procedures, strong cybersecurity, responsible data governance, and clear communication about how genomic information is used.

How Is Genetic Testing Developing Across Major European Markets?

United Kingdom

The United Kingdom is one of Europe's advanced genetic testing markets, supported by established genomic medicine programs, biomedical research capabilities, and developed healthcare infrastructure. Genetic testing is increasingly being integrated into oncology, inherited disease diagnosis, reproductive healthcare, and pharmacogenomics.

Government funding has also played an important role. The provided source states that more than £200 million has recently been committed to genomics initiatives, supporting research, innovation, and collaboration across the healthcare ecosystem.

The country's continued emphasis on genomic medicine and digital healthcare should support further integration of testing into routine clinical practice.

Germany

Germany has a strong healthcare and research environment that supports genetic testing adoption. Hospitals and diagnostic laboratories are expanding genomic capabilities for hereditary diseases, cancer diagnosis, personalized medicine, and precision therapeutics.

Investment in sequencing technologies, molecular diagnostics, and bioinformatics is improving the country's capacity to manage complex genomic information. Collaboration between healthcare, academic, and research institutions also supports continued innovation.

France

France is strengthening its genetic testing ecosystem through investment in genomic research, clinical innovation, and personalized healthcare. Genetic testing is increasingly applied to inherited disorders, oncology, reproductive medicine, and disease diagnosis.

Modern laboratory technologies and greater integration of genomic medicine into healthcare are supporting adoption. Increasing awareness of preventive healthcare and genetic counseling is also helping broaden the role of genetic diagnostics.

Italy

Italy's genetic testing market is developing as hospitals, research institutions, and specialized laboratories expand access to genomic diagnostics. Applications include rare diseases, cancer, prenatal testing, cardiovascular genetics, and pharmacogenomics.

Investment in sequencing, laboratory automation, and bioinformatics is improving diagnostic capabilities. Greater awareness of inherited disease prevention and personalized treatment is also supporting market development.

What Are the Key Segments of the Europe Genetic Testing Market?

By Type

The market can be segmented into:

• Predictive testing
• Carrier testing
• Prenatal and newborn testing
• Diagnostic testing
• Pharmacogenomic testing
• Nutrigenomic testing
• Others

By Product

The major product categories include:

• Consumables
• Equipment
• Software and services

By Technology

Genetic testing technologies include:

• Polymerase chain reaction
• DNA sequencing
• Microarrays
• Others

By Disease

Applications span:

• Cancer
• Genetic diseases
• Cardiovascular diseases
• Rare diseases
• Infectious diseases
• Others

By End User

Key end users include:

• Hospitals and clinics
• Diagnostic laboratories
• Others

What Is the Future Outlook for the Europe Genetic Testing Market?

The future of genetic testing in Europe is closely connected to the broader transformation of healthcare toward prevention, precision, and individualized treatment. As genomic information becomes increasingly integrated into clinical decision-making, demand is likely to expand across oncology, rare diseases, reproductive health, pharmacogenomics, and population screening.

The market's projected increase from US$7.25 billion in 2025 to US$14.61 billion by 2034, at a CAGR of 8.1% during 2026–2034, reflects the growing role of genomic technologies in European healthcare.

Future progress will depend not only on technological innovation but also on reimbursement policies, skilled professionals, patient awareness, ethical data management, and equitable access to testing. Expanding newborn screening, hereditary cancer testing, comprehensive sequencing, and digital genomic services could create substantial opportunities throughout the forecast period.

Frequently Asked Questions

1. What is the Europe genetic testing market size in 2025?

According to the provided Renub Research forecast, the Europe genetic testing market is valued at US$7.25 billion in 2025.

2. How large will the Europe genetic testing market be by 2034?

The market is expected to reach US$14.61 billion by 2034, according to the provided forecast.

3. What is the expected CAGR of the Europe genetic testing market?

The Europe genetic testing market is projected to grow at a CAGR of 8.1% from 2026 to 2034.

4. What is driving genetic testing market growth in Europe?

Key drivers include precision medicine, newborn and population screening, hereditary cancer testing, NGS-based comprehensive panels, technological innovation, greater awareness of inherited disorders, and wider genomic healthcare adoption.

5. Why is next-generation sequencing important for genetic testing?

Next-generation sequencing can examine many genes simultaneously, improving the ability to identify genetic variations associated with complex diseases. It is particularly valuable in oncology and rare-disease diagnosis.

6. What is the biggest challenge facing genetic testing in Europe?

A shortage of qualified genetic counselors is a major challenge because patients often need professional guidance before and after testing. Ethical, legal, privacy, reimbursement, and access issues are also important considerations.

7. Which applications are expected to support future market growth?

Newborn screening, hereditary cancer testing, rare-disease diagnosis, prenatal testing, pharmacogenomics, oncology, and precision medicine are among the important application areas supporting the European genetic testing market.

Conclusion

The Europe genetic testing market is moving toward a more integrated role within mainstream healthcare. Advances in sequencing, bioinformatics, artificial intelligence, and laboratory technologies are making genetic information increasingly useful for diagnosis, prevention, and treatment decisions.

At the same time, expanding newborn screening, hereditary cancer testing, and comprehensive genomic panels are creating new sources of demand. Strong healthcare infrastructure and government-supported genomic initiatives provide additional momentum across major European countries.

However, sustained growth will require more trained genetic counselors, responsible genomic data management, effective reimbursement frameworks, and accessible testing services. With the market forecast to reach US$14.61 billion by 2034 from US$7.25 billion in 2025, the European genetic testing industry is positioned for significant expansion as healthcare systems continue moving toward precision and preventive medicine.